BOSTON, Mass., August 30, 2023— WaveBreak announced today the presentation of new preclinical data for its first-in-class, oral inhibitors of α-synuclein oligomer generation demonstrating efficacy for blocking the progression of both α-synuclein oligomers and aggregates in cell and mouse models of Parkinson’s disease. The data were presented in a poster presentation today at the MDS International Congress of Parkinson’s Disease and Movement Disorders® taking place August 27–31 in Copenhagen.

“We are excited by the findings from these latest studies, which used state-of-the art in vitro and in vivo models and analytical techniques to measure the ability of our small-molecule candidates to inhibit the production of α-synuclein oligomers and aggregates,” said John Thomson, Chief Scientific Officer of WaveBreak. “These data add to the growing body of preclinical evidence supporting the disease-modifying profile of WaveBreak’s small-molecule inhibitors, which interrupt the molecular mechanisms at the source of toxic oligomer formation with high precision and specificity.”

Highlights of the presentation follow, and the poster is available on WaveBreak’s website: https://wavebreaktx.com/our-science/publications

Poster #1461: “Small molecule inhibitors for precise inhibition of α-synuclein oligomer generation in Parkinson’s disease (PD)”
Presenter: Andrew Cridland

Summary and key findings:
A WaveBreak oral, small-molecule inhibitor of α-synuclein oligomer generation—WTX-A—demonstrated potent reduction of α-synuclein oligomers and aggregates in cell and mouse models of Parkinson’s disease. Specifically:

  • WTX-A inhibited 90% of both primary nucleation and secondary nucleation—the molecular mechanisms at the source of α-synuclein oligomer formation—with high specificity for α-synuclein, showing no inhibition in tau and Aβ42 amyloid aggregation assays.
  • WTX-A significantly reduced α-synuclein oligomer levels in a dose-dependent manner in iPSC-derived dopaminergic cells (seeded with human fibrils), in mouse primary neuron cells (seeded with murine fibrils), and in SNCA triplication iPSC-derived cortical neuron cells.
  • In the gold-standard M83 transgenic mouse model (expressing aggregation-prone human A53T mutant, seeded with human fibrils), WTX-A reduced α-synuclein aggregates by ~70%—substantively more than measured with a different first-generation WaveBreak small molecule.

WaveBreak Technology Platform
The relatively recent understanding that oligomers resulting from errant protein folding are the toxic entities directly responsible for neurotoxicity in Parkinson’s disease, Alzheimer’s disease, and ALS has defined a new approach to treating a central molecular cause of neurodegeneration. Yet characterizing and suppressing these fleeting protein intermediates is one of the most challenging problems in drug discovery for scientists working with protein assembly reactions: Because these protein forms are highly transient, they cannot simply be put in a bottle and analyzed in isolation, which makes them difficult to target using conventional single-target drug discovery approaches. Targeting the complex, highly interconnected network of interactions that lead to oligomer formation in neurodegenerative diseases requires a fundamentally different approach to measure, assay, and analyze the proteins during their evolving assembly and disassembly process, from their formation to their disappearance. WaveBreak’s technology platform enables analysis of the inhibition of the source mechanisms that produce oligomer intermediates in complex disease processes. We are leveraging this approach to discover and develop small molecule therapeutics that inhibit oligomer generation at the source of these protein aggregation assembly pathways with specificity and precision.

About Parkinson’s Disease
One million people in the U.S. and up to 10 million people worldwide are living with Parkinson’s disease (PD). With nearly 90,000 people in the U.S. diagnosed each year, PD is the fastest-growing neurologic disease in the U.S. and is expected to affect 1.2 million people by 2030. The accumulation of aggregated α-synuclein protein in neurons is a hallmark of the disease, with progressive development of both motor and non-motor symptoms. The therapeutics available today treat a subset of PD symptoms, and there are currently no treatments available that are disease-modifying and slow the progression of PD.

About WaveBreak
WaveBreak is a biopharmaceutical company transforming drug discovery for neurodegenerative diseases, targeting the fleeting protein intermediates central to many disease pathways that are beyond the reach of conventional drug discovery approaches. We have built a unique drug discovery platform to target the transient protein intermediates—the oligomers—in these disease pathways, to interrupt the molecular mechanisms that are the source of oligomer generation with small-molecule therapeutics. We are focusing this platform first on some of the greatest unmet medical needs of our time: Parkinson’s disease, Alzheimer’s disease, and ALS. For more information, please visit: www.wavebreaktx.com.

Contact:
Mary Moynihan
M2Friend Biocommunications
+1 (802) 951-9600
mary@m2friend.com

BOSTON, Mass., April 25, 2023— Wren Therapeutics announced today that the company has changed its name to WaveBreak. This new name reflects the company’s focus on developing small-molecule therapeutics that inhibit the production of fleeting protein intermediates—the oligomers—that are at the source of the protein misfolding and aggregation assembly pathways in the major neurodegenerative diseases.

“We are making strong progress in the development of a new class of oral, small-molecule therapeutics for neurodegenerative diseases, focusing first on inhibiting α-synuclein oligomers and aggregation for the treatment of Parkinson’s disease,” said Bart Henderson, CEO. “Our goal is to break open a new frontier of treatment for the rapidly expanding and debilitating wave of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, and ALS that have enormous unmet medical need.”

WaveBreak’s Technology Platform
The relatively recent understanding that oligomers resulting from errant protein folding are the toxic entities directly responsible for neurotoxicity in Parkinson’s disease, Alzheimer’s disease, and ALS has defined a new approach to treating a central molecular cause of neurodegeneration. Yet characterizing and suppressing these fleeting protein intermediates is one of the most challenging problems in drug discovery for scientists working with protein assembly reactions: Because these protein forms are highly transient, they cannot simply be put in a bottle and analyzed in isolation, which makes them difficult to target using conventional single-target drug discovery approaches. Targeting the complex, highly interconnected network of interactions that lead to oligomer formation in neurodegenerative diseases requires a fundamentally different approach to measure, assay, and analyze the proteins during their evolving assembly and disassembly process, from their formation to their disappearance. WaveBreak’s technology platform enables analysis of the inhibition of the source mechanisms that produce oligomer intermediates in complex disease processes. It is a network-centric approach to enable the discovery of small molecules that can block their generation with specificity and precision.

About WaveBreak
WaveBreak is a biopharmaceutical company transforming drug discovery for neurodegenerative diseases, targeting the fleeting protein intermediates central to many disease pathways that are beyond the reach of conventional drug discovery approaches. We have built a unique drug discovery platform to target the transient protein intermediates—the oligomers—in these disease pathways, to interrupt the molecular mechanisms that are the source of oligomer generation with small-molecule therapeutics. We are focusing this platform first on some of the greatest unmet medical needs of our time: Parkinson’s disease, Alzheimer’s disease, and ALS. For more information, please visit: www.wavebreaktx.com.

Contact:
Mary Moynihan
M2Friend Biocommunications
+1 (802) 951-9600
mary@m2friend.com

BOSTON, Mass., March 29, 2023— Wren announced today the presentation of preclinical data for its first-in-class, oral inhibitors of α-synuclein oligomer generation demonstrating potent inhibition of both oligomer production and aggregate formation in cell and mouse models used for studying Parkinson’s disease progression. The data were presented in poster and oral presentations today at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2023) taking place from March 28–April 1 in Gothenburg, Sweden.

“α-Synuclein oligomers are fleeting protein intermediates implicated in the molecular damage and cellular destruction that decimate dopaminergic neurons in Parkinson’s disease and other α-synucleinopathies. Unfortunately, their elusive, ephemeral physical nature makes them difficult to target using conventional drug discovery approaches, as well as to develop biomarkers to support clinical development,” said Bart Henderson, CEO of Wren. “We are taking a different approach to drug discovery, using biophysics to design landmark therapeutics that can address the urgent need for effective drugs for this rapidly expanding neurodegenerative disease. In parallel, we are advancing the latest biomarker technologies to guide preclinical and clinical development to increase the probability of clinical success. We are excited about our progress and the promising initial data we presented today for several oral, small-molecule oligomer inhibitors and for the biomarker technologies we are deploying to measure on-target efficacy in both preclinical and clinical studies.”

The relatively recent understanding that α-synuclein oligomers resulting from errant protein folding are the toxic entities directly responsible for neurotoxicity in PD has defined a new approach to treating a central molecular cause of neurodegeneration in Parkinson’s disease. Yet characterizing and suppressing transient protein intermediates is one of the most challenging problems in drug discovery for scientists working with protein assembly reactions, because these protein forms are highly transient and cannot simply be put in a bottle and analyzed in isolation. Targeting the complex, highly interconnected process of α-synuclein formation in Parkinson’s disease requires a different approach to measure, assay, and analyze the proteins during their evolving assembly and disassembly, from their formation to their disappearance. This requires targeting a network of interactions that is a fundamentally different approach from conventional single-target drug discovery.

Wren’s technology platform enables the analysis of the inhibition of the source mechanisms that produce oligomer intermediates in complex disease processes. It is a network-centric approach to enable the discovery of small molecules that can block their generation with specificity and precision. Today’s presentations are the first data Wren has presented publicly that demonstrate the therapeutic potential of a new class of oral, small-molecule therapeutics developed using this technology platform for targeting the fleeting intermediates at the core of neurodegeneration.

Highlights of the presentations follow, and the posters are available on Wren’s website: https://wavebreaktx.com/our-science/publications

Poster #825 / On-Demand Oral Presentation OD188: “The selective detection of alpha-synuclein oligomers to analyze small molecule inhibitors of their formation for the treatment of Parkinson’s disease”*
Presenter: Samata Pandey

Poster #729: “Reducing toxic alpha-synuclein oligomers in PD through precise targeting of the molecular mechanisms of oligomer formation with small molecule inhibitors”*
Presenter: Sarah Ball

*Special thanks to Eisai, which collaborated with Wren in conducting some of these studies

Summary and key findings:
Wren has developed oral small molecules that target the molecular mechanisms at the source of oligomer generation: Primary nucleation, which is catalyzed by lipid membranes; and secondary nucleation, which is catalyzed by α-synuclein aggregates. In addition, Wren is developing biomarker assays for the selective detection of α-synuclein toxic oligomers that will enable biomarker-driven clinical development for these small-molecule therapeutics. In these studies, several oral, small-molecule inhibitors of α-synuclein oligomer generation demonstrated potent reduction of both oligomers and aggregates in vitro, and in both cellular and in vivo models. Specifically:

  • The researchers used proprietary in vitro biochemical assays designed to measure kinetic rates of oligomer generation with high precision to optimize small-molecule oligomer inhibitors for enhanced potency and oral pharmacokinetics, with good brain penetration.
  • These small-molecule compounds inhibited both molecular mechanisms of α-synuclein oligomer formation in these assays at low drug concentrations, with high specificity, without inhibiting either amyloid beta or Tau aggregation.
  • The researchers also presented data for two different biomarker detection assays that use homotypic antibodies with high affinity and high specificity for α-synuclein oligomers—in a Sandwich ELISA assay and with a Proximity Ligation Assay (PLA).
  • The small-molecule inhibitors significantly reduced both α-synuclein oligomer levels and α-synuclein aggregates in a dose-dependent manner in iPSC dopaminergic cells (measured with both ELISA and PLA) and in the Line 61 transgenic mouse models (ELISA and pS129).

About Parkinson’s Disease
One million people in the U.S. and up to 10 million people worldwide are living with Parkinson’s disease (PD). With nearly 90,000 people in the U.S. diagnosed each year, PD is the fastest-growing neurologic disease in the U.S. and is expected to affect 1.2 million people by 2030. The accumulation of aggregated α-synuclein protein in neurons is a hallmark of the disease, with progressive development of both motor and non-motor symptoms. The therapeutics available today treat a subset of PD symptoms, and there are currently no treatments available that are disease-modifying and slow the progression of PD.

About Wren Therapeutics
Wren is a biopharmaceutical company transforming drug discovery for neurodegenerative diseases, targeting the fleeting protein intermediates central to many disease pathways that are beyond the reach of conventional drug discovery approaches. We have built a unique drug discovery platform to assay and target the transient protein intermediates—the oligomers—in these disease pathways, to interrupt the molecular mechanisms that are the source of oligomer generation with small-molecule therapeutics. We are focusing this platform first on some of the greatest unmet medical needs of our time: Parkinson’s disease, Alzheimer’s disease, and ALS. For more information, please visit: www.wrentherapeutics.com.

Contact:
Mary Moynihan
M2Friend Biocommunications
+1 (802) 951-9600
mary@m2friend.com


* Renamed WaveBreak in 2023

BOSTON, Mass., January 4, 2023— Wren Therapeutics announced today a number of new members to its Scientific Advisory Board. Joining existing members—Tuomas Knowles, PhD; Sara Linse, PhD; and Michele Vendruscolo, PhD—are Jeffrey L. Cummings, MD, ScD; Nora Bengoa-Vergniory, PhD; Bradley Hyman, MD, PhD; Kelvin Luk, PhD, MTR; and Rajesh Pahwa, MD.

“We are breaking new ground, and we are relying on this distinguished and diverse group of experts to guide our translational and clinical development strategy for our pioneering class of small-molecule drugs that target the source of oligomer generation in neurodegenerative diseases,” said Bart Henderson, CEO of Wren. “Each of our SAB members brings unrivaled scientific expertise across key areas of neurodegenerative disease biology, preclinical development, and clinical testing that will be invaluable as we advance our first-in-class small-molecule drugs for Parkinson’s disease, Alzheimer’s disease, and ALS into clinical trials.”

Jeffrey L. Cummings, MD, ScD
Joy Chambers-Grundy Professor of Brain Science, Director of the Chambers-Gundy Center for Transformative Neuroscience, Co-Director of the Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada, Las Vegas
Dr. Cummings is globally recognized for his contributions to Alzheimer’s disease research, drug development, and clinical trials. He has been recognized for this research and leadership contributions in the field of Alzheimer’s disease through numerous awards. More at: https://www.unlv.edu/people/jeffrey-l-cummings-md-scd

Nora Bengoa-Vergniory, PhD
Ikerbasque and Ramon y Cajal Research Fellow, Achucarro Basque Center for Neuroscience, Spain
Research Visitor, Oxford University
Dr. Bengoa-Vergniory’s research focuses on alpha-synuclein aggregation and neuroinflammation in neurodegeneration, specifically in Parkinson’s and Alzheimer’s diseases. Her laboratory specializes in the identification and treatment of disease targets in neurodegenerative conditions through translational modeling. More at: https://www.ikerbasque.net/en/nora-bengoa-vergniory and https://www.dpag.ox.ac.uk/team/nora-bengoa-vergniory

Bradley Hyman, MD, PhD
Director, Massachusetts Alzheimer’s Disease Research Center
Dr. Hyman directs the Alzheimer’s disease research unit at the MassGeneral Institute for Neurodegenerative Disease (MIND) with the goal of understanding the neuropathophysiologic and genetic factors that underlie dementia. His laboratory studies the anatomical and molecular basis of dementia in Alzheimer’s disease and dementia with Lewy bodies. More at: https://www.massgeneral.org/neurology/research/hyman-lab

Kelvin Luk, PhD, MTR
Research Associate Professor of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine and Penn Center for Neurodegenerative Disease Research (CNDR)
Dr. Luk’s research aims to untangle the relationship between the formation of alpha-synuclein pathology that characterizes Parkinson’s disease and related disorders, such as dementia with Lewy bodies and multiple system atrophy (MSA), as well as its contribution to neuronal dysfunction and degeneration. More at: https://www.med.upenn.edu/apps/faculty/index.php/g275/p5426062

Rajesh Pahwa, MD
Laverne and Joyce Rider Professor of Neurology, Chief of the Parkinson’s and Movement Disorder Division, and Director of Parkinson Foundation Center of Excellence, University of Kansas Medical Center
Dr. Pahwa’s research focuses on the various aspects of Parkinson’s disease and essential tremor. He has conducted more than 150 clinical trials for Parkinson’s disease therapeutics and for other movement disorders. More at: https://www.kumc.edu/rpahwa.html

About Wren Therapeutics
Wren is a biopharmaceutical company transforming drug discovery for neurodegenerative diseases, targeting the fleeting protein intermediates central to many disease pathways that are beyond the reach of conventional drug discovery approaches. We have built a unique drug discovery platform to assay and target the transient protein intermediates—the oligomers—in these disease pathways, to interrupt the molecular mechanisms that are the source of oligomer generation with small-molecule therapeutics. We are focusing this platform first on some of the greatest unmet medical needs of our time: Parkinson’s disease, Alzheimer’s disease, and ALS. For more information, please visit: www.wrentherapeutics.com.

Contact:
Mary Moynihan
M2Friend Biocommunications
+1 (802) 951-9600
mary@m2friend.com


* Renamed WaveBreak in 2023

— Executive leaders in R&D management, medicinal chemistry, technical operations, and translational biology to lead build-out of discovery platform and pipeline —

BOSTON, Mass., December 8, 2022— Wren Therapeutics announced today a number of senior leadership appointments as the company advances its first investigational therapies toward the clinic, based on the company’s breakthrough approach to discovering small molecules that precisely target and shut down the sources of oligomer and aggregate generation in neurodegenerative diseases.

The company recently welcomed Vertex Pharmaceuticals veterans John Thomson, PhD and Patrick Connelly, PhD as its Chief Scientific Officer and first Chief Innovation Officer, respectively. Dr. Thomson and Dr. Connelly are Vertex founding scientists who worked together on leadership teams that discovered and developed Vertex’s seven FDA-approved drugs.

In addition to Drs. Thomson and Connelly, new appointments to Wren’s leadership team include:

  • Mike Dey, PhD: Head of Manufacturing and Technical Operations
  • Janeta Popovici-Muller, PhD: Head Drug Design and Advancement
  • Rajeev Sivasankaran, PhD: Head Translational Development

“It is often said that drug discovery and development is the ultimate team sport—it takes a great many people with immense talent, dedication, and focus working together on breakthrough science,” said Bart Henderson, CEO of Wren. “We couldn’t be more pleased to welcome John, Pat, Mike, Janeta, and Rajeev to Wren’s team—all proven executives in their fields. With this lineup of experienced talent, Wren has the leadership team to break open the field of neurodegenerative diseases targeting the molecular mechanisms at the source of toxic oligomer generation.”

John Thomson, PhD | Chief Scientific Officer
Dr. Thomson was formerly Head of Research for Vertex Pharmaceuticals’ USA-based research operations, a company he helped to build from the ground up. During his 25-year tenure, he was involved with all Vertex research programs spanning antivirals and anti-infectives, immunoregulation, inflammation, neurological dysfunction, cystic fibrosis, and oncology research. He headed the Hepatitis C project that yielded INCIVEK® (telaprevir) and contributed to the discovery and selection of more than 40 development candidates—many first-in-class, and of which six were eventually approved as drugs.

Patrick Connelly, PhD | Chief Innovation Officer
Dr. Connelly is a biophysics expert who created and led a number of specialized R&D business units at Vertex Pharmaceuticals, where he was a founding scientist and former employee. He established the unique Materials Discovery & Characterization development function at Vertex, where he, his staff, and colleagues co-invented three first-in-class medicines—INCIVEK® for hepatitis C, and KALYDECO® and ORKAMBI® for cystic fibrosis. Dr. Connelly also co-founded and led Vertex’s Corporate Innovation unit that catalyzed the company’s entry into sickle cell disease and was a member of the Vertex-CRISPR Therapeutics Joint Research Committee that brought forth Exa-cel, one of the first gene-editing medicines to be tested in humans, currently in Phase 3 clinical trials.

Mike Dey, PhD | Head of Manufacturing and Technical Operations
Dr. Dey’s extensive experience in drug development, industrialization, and manufacturing encompasses more than 40 NDA/BLA approvals. Previous to joining Wren, Dr. Dey was Vice President, Pharmaceutical Development and Vice President, Endocrinology Strategy team at Ipsen, where he supported Somatuline in becoming a $1 billion product as well as out-licensing partnerships on early products that are now approved life-changing therapies. He held senior manufacturing and R&D positions at Aventis (now Sanofi) in various mergers for which he led integration of industrialization and R&D teams to accelerate new products. He has developed novel equipment and built facilities in the U.S., EU, and Asia to secure supply from earliest clinical trials to global launches. He is an inventor of multiple formulation and drug delivery patents supporting several approved products.

Janeta Popovici-Muller, PhD | Head of Drug Design & Advancement
Dr. Popovici-Muller has more than 20 years of experience in early and late-stage drug discovery. She was a founding employee and Senior Vice President, Head of Drug Discovery at Rectify Pharmaceuticals and served as Vice President, Head of Chemistry at Decibel Therapeutics. Dr. Popovici-Muller co-led drug discovery programs at Agios Pharmaceuticals that delivered clinical-stage molecules in the areas of cancer metabolism (co-inventor of Tibsovo®) and rare genetic metabolic disorders (Pyrukynd®). Preceding her tenure at Agios, Dr. Popovici-Muller spent 10 years at Merck Research Labs in Cambridge, MA (through merger with Schering-Plough) focused on small-molecule drug discovery in oncology, inflammation, and anti-viral therapeutic areas.

Rajeev Sivasankaran | [Head of Translational Development
Dr. Sivasankaran joined Wren as Head of Translational Development after an 18-year tenure at the Novartis Institutes of Biomedical Research (NIBR) leading drug discovery programs ranging from small molecules to gene therapy—from early ideation to human clinical trials—most recently as Executive Director and Head of Rare Diseases in the Neuroscience Division. His group initiated and advanced drug discovery programs focused on a broad range of monogenic neurodegenerative and neurodevelopmental diseases including spinal muscular atrophy, Huntington’s disease, Friedreich’s ataxia, and autism spectrum disorders.

About Wren Therapeutics
Wren is a biopharmaceutical company transforming drug discovery for neurodegenerative diseases, targeting the fleeting protein intermediates central to many disease pathways that are beyond the reach of conventional drug discovery approaches. We have built a unique drug discovery platform to assay and target the transient protein intermediates—the oligomers—in these disease pathways, to interrupt the molecular mechanisms that are the source of oligomer generation with small-molecule therapeutics. We are focusing this platform first on some of the greatest unmet medical needs of our time: Parkinson’s disease, Alzheimer’s disease, and ALS. For more information, please visit: www.wrentherapeutics.com.

Contact:
Mary Moynihan
M2Friend Biocommunications
+1 (802) 951-9600
mary@m2friend.com


* Renamed WaveBreak in 2023

CAMBRIDGE, United Kingdom, BOSTON, Mass. March 4, 2022 – Wren Therapeutics, a biopharmaceutical company transforming drug discovery for neurodegenerative diseases, today announced the appointment of Bart Henderson as Chief Executive Officer. Wren’s unique drug discovery platform harnesses advances in the biophysics of protein assembly dynamics to target the toxic fleeting protein intermediates, the oligomers, in neurodegenerative disease pathways, and discover small molecules that can block their generation with precision.

Bart brings broad leadership experience in the biotechnology industry as a founder and co-founder of several companies including Torque (now Repertoire Immune Medicines), Rhythm (Nasdaq: RYTM) and its subsidiary Motus (acquired by Allergan) and has been an operating partner at Flagship Pioneering as well as an entrepreneur-in-residence at MPM Capital. He joins Wren at a time of significant advancement of its two lead programs targeting amyloid-β for Alzheimer’s disease and α-synuclein for Parkinson’s disease and other synucleinopathies.

Kelly Martin, Chairman of the Board, commented:

On behalf of the Board of Directors and our investors, I want to thank Dr. Samuel Cohen, scientific co-founder and founding CEO of Wren, for his many exceptional contributions to the company. Wren has made substantive progress under his leadership, advancing the drug discovery platform and pipeline, establishing our first discovery collaboration, and bringing together a world-class team and group of investors. Sam will continue to contribute to the Company’s future direction as a member of the board of directors.

As we pivot toward the future, I enthusiastically welcome Bart to the Wren team as our next CEO. We are fortunate to have a leader with such an outstanding and unique track record for creating value and advancing companies. His leadership will be a huge asset for the company as we expand and advance our pipeline into the clinic.

Bart Henderson Chief Executive Officer of Wren, commented:

I am excited and highly energized to lead and work alongside this outstanding team at Wren and to build on what has already been accomplished with the Company’s proprietary technology platform for previously intractable diseases. This technology has the ability to deliver unparalleled predictive capability for creating breakthrough drugs for major neurologic and other diseases that involve protein aggregation—a dynamic and complex biophysical process that is beyond the reach of conventional drug discovery approaches.

About Wren

Wren is a biopharmaceutical company transforming drug discovery for neurodegenerative diseases, targeting the fleeting protein intermediates central to many disease pathways that are beyond the reach of conventional drug discovery approaches. We have built a unique drug discovery platform to assay and target the transient protein intermediates in these disease pathways, the oligomers, to interrupt the molecular mechanisms that are the source of oligomer generation with small molecule therapeutics. We are focusing this platform first on two of the greatest unmet medical needs of our time: Alzheimer’s disease and Parkinson’s disease. For more information, please visit: www.wrentherapeutics.com

Contact:

Wren Therapeutics
Emer Reynolds
communications@wrentherapeutics.com


* Renamed WaveBreak in 2023
Back to Top